Tigris Pharmaceuticals, Inc

Tigris Pharmaceuticals, Inc. is a venture-backed clinical-stage biopharmaceutical company that commercially develops innovative products for the treatment of important unmet medical needs in cancer and infectious diseases. Tigris is focusing its efforts on the development, testing and commercialization of its lead compound, A-007, as a non-invasive treatment for both pre-cancerous HPV-induced lesions and for invasive epithelial cancers. A key component of Tigris' strategy is to acquire global rights to additional product candidates in oncology and infectious diseases, while continuing to use its technology platform to develop and commercialize new products and line extensions.

Contact Details: 3359 Woods Edge Circle, Ste 103 Bonita Springs Florida 34134 United States of America Tel: 239.444.5400 Fax: 321.206.8627 Email: info@tigrispharma.com WWW: www.tigrispharma.com/

Loading...

Press Releases on Tigris Pharmaceuticals, Inc:
First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418	1st May, 2009	Tigris Pharmaceuticals, Inc.	BONITA SPRINGS, Fla., May 1 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, announced today that dosing has started in a Phase I clinical trial of GGTI-2418.
Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting	30th April, 2009	Tigris Pharmaceuticals, Inc.	BONITA SPRINGS, Fla., April 30 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, announced that preclinical data were presented on its novel molecule, AFP-464,
Tigris Pharmaceuticals Appoints Pedro Granadillo as Chairman of Board of Directors	16th April, 2009	Tigris Pharmaceuticals, Inc.	BONITA SPRINGS, Fla., April 16 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held company developing targeted cancer treatment therapies, today announced the appointment of Pedro
FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceutical's GGTI-2418	4th March, 2009	Tigris Pharmaceuticals, Inc.	BONITA SPRINGS, Fla., March 4 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, today announced that its Investigational New Drug (IND) application for the
Tigris Pharmaceuticals Files IND Application for GGTI-2418	6th February, 2009	Tigris Pharmaceuticals, Inc.	BONITA SPRINGS, Fla., Feb. 6 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, announced today that it has filed an Investigational New Drug (IND) application

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 347 times since April 2007, the link to the organisation's website has been followed 50 times

Recent Search Terms used to find this page: tigris pharma | tigris company | tigris pharmaceuticals | tigris company plc | TIGRIS 007 2009 | .

Search for more companies in Bonita Springs

Search for more companies in Florida

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Tigris Pharmaceuticals, Inc